Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,727 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Clinical trials
11,611 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03563482 | Correlation of Metabolic Imaging With Immune Markers in NSCLC Candidate to Immunotherapy. | unknown | N/A | 500 | Istituto Clinico HumanitasOTHER | 1 | Apr 28, 2022 | clinicaltrials |
| NCT05351320 | WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC | unknown | Phase 2 | 40 | Jinming YuOTHER | 1 | Apr 28, 2022 | clinicaltrials |
| Comparison of Two Techniques of Uniportal VATS Lobectomies for Clinical Stage I Non-Small Cell Lung Cancer |
| unknown |
| N/A |
| 20 |
| Pulmonary Hospital ZakopaneOTHER |
| 1 |
| Apr 26, 2022 |
| clinicaltrials |
| NCT04743752 | Obstructive Sleep Apnea Influences Efficacy of PD-1-Based Immunotherapy Against Non-Small Cell Lung Cancer | unknown | — | 200 | Peking University First HospitalOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT05346952 | A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC). | unknown | Phase 3 | 390 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 26, 2022 | clinicaltrials |
| NCT03679936 | Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions and Differentiating Multiple Primary Lung Cancer From Intrapulmonary Metastases of Non-small Cell Lung Cancer | unknown | — | 120 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT04948047 | Breath Combined With CT for Diagnoses of Pulmonary Nodules | unknown | — | 900 | Peking University People's HospitalOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT05326425 | Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI. | unknown | Phase 2 | 40 | Jin Hyoung KangOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT03711305 | Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) | unknown | Phase 3 | 462 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 18, 2022 | clinicaltrials |
| NCT05332171 | Examination Of Exercise Adherence İn Lung Cancer Patients Given Calisthenic Exercise | unknown | N/A | 30 | Hasan Kalyoncu UniversityOTHER | 1 | Apr 18, 2022 | clinicaltrials |
| NCT04759651 | Sleep Disorders in Patients With Suspected Lung Cancer Before and After Thoracic Surgery | unknown | — | 1,200 | Koç UniversityOTHER | 1 | Apr 15, 2022 | clinicaltrials |
| NCT05329298 | A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 90 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 15, 2022 | clinicaltrials |
| NCT05319145 | PeRsonalizing the Approach to the Oncologic Frail Individual Through Tailored Assessment and Intervention (PROFIT Study)(PROFIT) | unknown | N/A | 268 | Hospital Universitari Vall d'Hebron Research InstituteOTHER | 2 | Apr 13, 2022 | clinicaltrials |
| NCT05320458 | Pulmonary Rehabılıtatıon Wıth Non-Small Lung Cancer | unknown | N/A | 11 | Hasan Kalyoncu UniversityOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT02817945 | Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging | unknown | Early Phase 1 | 100 | Peking Union Medical College HospitalOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT01441349 | Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer | unknown | Phase 2 | 192 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT01470716 | Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations | unknown | Phase 2 | 26 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03612154 | Study of Lorlatinib in ROS1 Rearranged NSCLC | unknown | Phase 2 | 35 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03808480 | Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10% | unknown | Phase 2 | 22 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT04040361 | Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY) | unknown | Phase 2 | 24 | Masahiro TsuboiOTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT05314296 | Osimertinib for Russian EGFR T790M Mutation-positive NSCLC Patients Who Progressed on or After EGFR TKI Therapy(TRUST) | unknown | — | 70 | N.N. Blokhin National Medical Research Center of OncologyOTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT02637531 | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | unknown | Phase 1 | 219 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05306847 | Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer | unknown | Phase 2 | 93 | Peking Union Medical College HospitalOTHER | 0 | Apr 1, 2022 | clinicaltrials |
| NCT04325763 | A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC) | unknown | Phase 3 | 315 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05299385 | The Study for Evaluating the Clinical Effectiveness and Safety of Respiratory Rehabilitation Software 'Redpill Breath'(COPD, Asthma, Lung Cancer, Etc.) | unknown | Phase 3 | 100 | Lifesemantics Corp.INDUSTRY | 1 | Mar 29, 2022 | clinicaltrials |
| NCT05299255 | Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer | unknown | Phase 2 | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 28, 2022 | clinicaltrials |
| NCT05236608 | A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC(ADIVO Lung) | unknown | Phase 1 / Phase 2 | 53 | National University Hospital, SingaporeOTHER | 1 | Mar 25, 2022 | clinicaltrials |
| NCT05296369 | Folic Acid Interferes With Radiation Esophagitis | unknown | N/A | 90 | Guizhou Medical UniversityOTHER | 1 | Mar 25, 2022 | clinicaltrials |
| NCT04828850 | Preoperative Lymph Node Staging With EBUS-TBNA in Clinical N0 Non Small-cell Lung Cancer | unknown | N/A | 50 | European Institute of OncologyOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT05287386 | A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy | unknown | Phase 2 | 20 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT05284994 | TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 160 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 17, 2022 | clinicaltrials |
| NCT05279521 | The Effect of Interventional Pulmonary Rehabilitation Exercise With Advanced Lung Cancer. | unknown | N/A | 104 | National Taiwan University HospitalOTHER | 0 | Mar 15, 2022 | clinicaltrials |
| NCT04228237 | LUng CAncer focuS - Long-term Monitoring of Bronchogenic Carcinoma Patients (LUCAS)(LUCAS) | unknown | — | 2,300 | Ceska Lekarska Spolecnost Jana Evangelisty Purkyne z.s.OTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT01951469 | Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer | unknown | Phase 3 | 160 | Sun Yat-sen UniversityOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT04690686 | Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC). | unknown | Phase 2 | 24 | Immunicom IncINDUSTRY | 1 | Mar 8, 2022 | clinicaltrials |
| NCT05267392 | Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy(IDEAR) | unknown | Phase 1 / Phase 2 | 30 | Instituto Portugues de Oncologia, Francisco Gentil, PortoOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT04956146 | Fruquintinib Combined With Sintilimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer | unknown | Phase 2 | 46 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT02607592 | A Prospective Multi-center Phase III Randomized Controlled Trial(NACA) | unknown | Phase 3 | 293 | Sun Yat-sen UniversityOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT05254132 | Artificial Intelligence for Help Non-Small Cell Lung Cancer: Measure Cancer Biology and Treatment Response Via Imaging(SALMON) | unknown | — | 1,000 | OncoRadiomicsINDUSTRY | 0 | Feb 24, 2022 | clinicaltrials |
| NCT05252065 | Cardiac Substructure Radiation Dose and Early Clinical Monitoring of Stage N2-3 Non-Small Cell Lung Cancer | unknown | — | 40 | Guizhou Medical UniversityOTHER | 0 | Feb 23, 2022 | clinicaltrials |
| NCT05252091 | An Exploratory Study of Herombopag for Thrombocytopenia Induced by Chemotherapy Combined With Immunotherapy in NSCLC | unknown | Phase 2 | 30 | Henan Cancer HospitalOTHER_GOV | 0 | Feb 23, 2022 | clinicaltrials |
| NCT05245994 | An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese | unknown | Phase 2 | 60 | Li Zhang, MDOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT05234138 | Generation Of a Lung Biobank for Future Use(GOLF) | unknown | — | 1,000 | Royal Marsden NHS Foundation TrustOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT05230563 | A Clinical Study of LUNG-CT CAD Decision Support | unknown | N/A | 8 | TaiHao Medical Inc.INDUSTRY | 1 | Feb 9, 2022 | clinicaltrials |
| NCT03801200 | Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC | unknown | Phase 2 | 90 | Hubei Cancer HospitalOTHER | 1 | Feb 8, 2022 | clinicaltrials |
| NCT02446704 | Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy | unknown | Phase 1 / Phase 2 | 66 | Zofia PiotrowskaOTHER | 1 | Feb 7, 2022 | clinicaltrials |
| NCT05137912 | Neoadjuvant Immunotherapy in Advanced NSCLC | unknown | — | 10 | Power Life Sciences Inc.INDUSTRY | 1 | Feb 7, 2022 | clinicaltrials |
| NCT05202249 | Effect of Muscle and Skin Fixation of Thoracic Drainage Tube on Postoperative Pain | unknown | N/A | 60 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Feb 4, 2022 | clinicaltrials |
| NCT05223595 | A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC | unknown | Phase 1 | 42 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 4, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Apr 28, 2022source: clinicaltrials